Hypericin

DB13014InvestigationalSmall molecule

Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.

Chemical structure of Hypericin
Formula / weight
C30H16O8 · 504.4432 g/mol (avg)
Also known as
HIPERICIN · Hypericum red
Code names
SGX301

Resolves to

Compound
UNII7V2F1075HDCAS548-04-9ChEMBLCHEMBL286494ChEBI5835PubChem5281051KEGGC07606
Clinical / RWD
RxNorm1546455
Structure
InChIKeyBTXNYTINYBABQR-UHFFFAOYSA-NSMILESCC1=C2C3=C(C)C=C(O)C4=C3C3=C5C2=C(C(O)=C1)C(=O)C1=C5C(=C(O)C=C1O)C1=C(O)C=C(O)C(C4=O)=C31
Targets
P08263GSTA1P09211GSTP1

What you can answer from here — as of September 16, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,052Drug interactionsStructured to mechanism, not free text
Sign in
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Hypericin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In